The size of the Asia Pacific Cell Fractionation Market was valued at USD 0.76 Billion in 2021. This value is further estimated to be growing at a CAGR of 10.7% and worth USD 1.27 Billion by 2026.
The high prevalence of diseases, the increase in government funding for research and development activities, the growing focus on personalized medicine, and the expansion of the biopharmaceutical and biotechnology industries drive APAC cell fractionation. Government and corporate investments have expanded significantly to drive the manufacturing and supply of medical supplies needed to treat chronic diseases, expected to drive Asia Pacific market growth. There is a significant need in research laboratories and institutes, increasing as the number of cultured cells processed for commercially diagnostic and research purposes grow due to the increased number of chronic diseases and infectious diseases, which has helped improve overall drug demand. A crucial development in this area is the requirement to isolate subcellular proteins from cultivated cells.
Advancements are bolstering the uptake in the cell fractionation market in the APAC region in various equipment and reagents. The microelectronic industry's use of microfabrication has set the tone for the present wave of product innovation in the cell fractionation sector. Given its great promise in cell lysis and single-cell analysis, Microfluidics has attracted a lot of attention in recent years. Increased frequency of chronic diseases, advances in research infrastructure, and favorable regulations for cell-based research to create novel products all have the potential to augment market growth. Because of the relevance of cell-based research, several government agencies have expanded their support for the expansion of such studies. Many government agencies have offered financial assistance in investments, funds, and grants.
Some of the major impediments are a lack of experienced people, the high expense of cell-based research, and the survival of new entrants and small players. As a result, small businesses and entrants to the cell fractionation market face substantial difficulty. In addition, R&D and market launch of innovative items necessitate large sums of money. As a result, corporations must invest extensively to remain competitive in the market.
This research report has been segmented and sub-segmented the Asia Pacific Cell Fractionation Market into the following categories.
By Product:
By Cell Type:
By End User:
By Country:
During the forecast period, the market in the Asia Pacific is expected to develop at the fastest rate. Government assistance for vaccine production, increased financing for cell-based research, cheap manufacturing costs, and the expanding focus of global market players on emerging Asian economies are all driving this industry's expansion. As a result, leading players in the plasma fractionation market will find Asia-Pacific a lucrative market. This is due to government bodies that control and supervise plasma collection, fractionation, and sales, which are the primary drivers of the plasma fractionation market.
Furthermore, rising incidences of medical problems such as high fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary and secondary immunological deficiencies are driving the industry forward. For players in the cell fractionation market, China, Brazil, and India present significant opportunities. The rising frequency of chronic diseases, advancements in research infrastructure, and favorable regulations for cell-based research in emerging countries are all contributing factors. As a result, major industry players are expanding their presence in emerging markets such as China by constructing new facilities and R&D and innovation centers.
KEY MARKET PLAYERS:
Some of the notable companies operating in the Asia pacific cell fractionation market profiled in the report are Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Product
5.1.1 Introduction
5.1.2 Consumables
5.1.3 Reagents
5.1.3.1 Enzymes
5.1.3.2 Detergent Solutions
5.1.4 Beads
5.1.5 Disposables
5.1.6 Instruments
5.1.6.1 Sonicator
5.1.6.2 Homogenizer
5.1.7 Y-o-Y Growth Analysis, By Product
5.1.8 Market Attractiveness Analysis, By Product
5.1.9 Market Share Analysis, By Product
5.2 Type of cell
5.2.1 Introduction
5.2.2 Microbial
5.2.3 Mammalian
5.2.4 Y-o-Y Growth Analysis, By Type of cell
5.2.5 Market Attractiveness Analysis, By Type of cell
5.2.6 Market Share Analysis, By Type of cell
5.3 End Users
5.3.1 Introduction
5.3.2 Research Laboratories and Institutes
5.3.3 Biopharmaceutical Companies
5.3.4 iotechnology Companies
5.3.5 Y-o-Y Growth Analysis, By End Users
5.3.6 Market Attractiveness Analysis, By End Users
5.3.7 Market Share Analysis, By End Users
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type of cell
6.1.3.4 By End Users
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type of cell
6.1.3.4 By End Users
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type of cell
6.1.3.4 By End Users
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Beckman Coulter
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Dickinson and Company
8.4 Bio-Rad Laboratories
8.5 Cell Signaling Technology
8.6 Miltenyi Biotec
8.7 Thermo Fisher Scientific Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
Related Reports
Apr 2021
